- Select a blog category
By Greg Reh, vice chairman, US and Global Life Sciences leader, Deloitte LLP
This week’s blog, by Greg Reh from the US firm, first appeared on the US Center for Health Solutions blog site. The blog features Greg’s commentary on the panel discussion from the Financial Times US Pharma and Biotech Summit about the changes needed to face coming innovations in manufacturing, pricing, and reimbursement of personalized therapies. These innovations include direct-to-payer models, mass customization, and valuation of gene therapies and one-time treatments, all of which present unique challenges to pharma companies’ current technology systems.
By Karen Taylor, Director, Centre for Health Solutions
Several weeks ago I participated in a panel discussion on inclusion and diversity in clinical trials. My research for the event and the discussion that ensued led me to conclude that while there have been some improvements, the pharma industry continues to struggle to recruit sufficient trial participants from important demographic groups, especially women, racial and ethnic minorities, and the elderly. As a result, the outcomes seen in clinical trials are likely to be unrepresentative of the patient outcomes in the real world.
By James Banham and Seb Zanker
This latest in our series of blogs on the challenges facing Integrated Care Systems (ICS), focuses on how some commissioners are embracing the proposed model of place-based, shared decision making described in the recent guidance from NHS England and NHS Improvement ‘Designing integrated care systems in England’1; and what steps they are taking to transition from transactional to more strategic activities.
By Nadeem Mohammed, Deloitte MCS Limited
Imagine the scene: it’s Friday night, eight senior executives at one of the world’s largest companies are sitting around a private dining table at a swanky city restaurant. They’re there to celebrate the closure of a transaction they’ve been toiling over for the past 12 months. You’re the Deal Lead, and you’ve just taken a congratulatory phone call from the Chief Executive – the Board are delighted with the acquisition, which will now be at the heart of the company’s growth strategy. You’ve given blood, sweat and tears on this – you raise a glass towards the table and take a quiet moment to reflect on what is surely a career defining moment.
Enabling Integrated Care Systems to improve health outcomes through robust population health analytics
By Jon White, Director, Public sector health analytics team
This blog is the third in our series of articles examining the challenges in establishing Integrated Care Systems (ICSs) and explores the critical role of population health analytics. Indeed, there is a growing realisation across the healthcare sector about the potential for data analytics to transform everything from strategic planning to clinical decision making. Today, data technology has already transformed many aspects of our lives with unprecedented access to information, connecting people and ideas in ways no-one would have predicted twenty years ago. We have all seen first hand how analytics has impacted other sectors such as retail and marketing and we are now entering a period of rapid innovation in the healthcare sector, with numerous opportunities to utilise data effectively. In this blog we are taking a pragmatic view of some of the things ICSs can do to work collaboratively and focus on improving population health outcomes.
By Cosima Pettinicchio, and Dr Eva de Brett, Deloitte MCS
Last month’s blog from our Deloitte healthcare practice provided an overview of the key challenges facing NHS and Local Authority organisations as they transition from Sustainability and Transformation Programmes (STPs) to Integrated Care Systems (ICSs); and gave a commitment to explore each of these challenges in more depth in a series of articles over the summer.1 This week’s blog explores the key building blocks of a comprehensive, target-oriented, Population Health Management (PHM) approach and outlines the ‘no-regrets’ decisions that system leaders need to consider when embarking on their transition to an ICS.
2019 Human Capital Trends: Reinvent with a human focus – the implications for the Life Sciences industry
By Shivani Maitra, Partner, Consulting
This time of year is always a highlight for me as it sees the publication of our annual Global Human Capital Trends report, based on the views of 10,000 survey respondents across 119 countries. This year’s findings reinforce the views of colleagues in the Life Sciences (LS) team, specifically that LS organisations need to rethink the workforce experience, adapt to a more diverse workforce and transform their approach to leadership development.
By Matthew Thaxter, Analyst, Centre for Health Solutions
Following the launch of our ninth annual report ‘Unlocking R&D productivity: Measuring the return from pharmaceutical innovation 2018’, we hosted a panel discussion in London to explore how innovation in the wider R&D ecosystem can unlock R&D productivity. Our panel of experts comprising representatives from big pharma, a small innovative biotech company, the ABPI and the Medicines Discovery Catapult discussed a wide range of topics including: the UK healthcare ecosystem, government policies in the UK aimed at supporting the life sciences industry, the evolving skills and talent agenda and the role of regulators in encouraging innovation. Below are some of the key highlights from the discussion.
By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions
Innovation and new technologies are acknowledged as key enablers of the digital transformation of the NHS, however, today, healthcare lags behind most other service industries in the adoption of technologies to improve performance and the service user experience. This week we launched our latest report, ‘Closing the digital gap: Shaping the future of UK healthcare’ which highlights the opportunities and future potential of digital technologies to tackle some of healthcare’s most intractable challenges.1 We acknowledge the numerous policy initiatives aimed at establishing ‘a digital NHS’, however, we also highlight a growing divide between policy ambition and the reality of the experience on the front-line.
By Catherine Skilton, Partner Deloitte’s Public Sector Healthcare team
As the first half of the year draws to a close, we in the Deloitte healthcare practice have decided to take stock and reflect on some of the key challenges facing NHS organisations as they come together to form Integrated Care Systems (ICSs). We have asked senior colleagues from across the firm to highlight the burning questions they are being asked about most frequently – and more importantly, what advice they provide.